Cargando…

Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma

Hepatocellular Carcinoma (HCC) is one of the most common cancers and a leading cause of cancer related death worldwide. Until recently, systemic therapy for advanced HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B or C, was limited and ineffective in terms of long-term survival. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shannon, Alexander H., Manne, Ashish, Diaz Pardo, Dayssy A., Pawlik, Timothy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405730/ https://www.ncbi.nlm.nih.gov/pubmed/37554167 http://dx.doi.org/10.3389/fonc.2023.1193762

Ejemplares similares

Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
por: Jiang, Joanna, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
por: Chiang, Chi-Leung, et al.
Publicado: (2019)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition
por: Kraus, Kim Melanie, et al.
Publicado: (2023)

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020)

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
por: Wu, Yaoqiang, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis
por: Yang, Xue-Gang, et al.
Publicado: (2022)

The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
por: Ozer, Muhammet, et al.
Publicado: (2021)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy
por: Vilas-Boas, Isabel, et al.
Publicado: (2022)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer
por: Smith, Jill P., et al.
Publicado: (2021)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016)

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Schubert, Philipp, et al.
Publicado: (2020)

Advances in radiotherapy and immunity in hepatocellular carcinoma
por: Yang, Yuhan, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
por: Sundar, Raghav, et al.
Publicado: (2020)

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
por: Lavoie, Jean-Michel, et al.
Publicado: (2022)

Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma
por: Ren, He, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_22tf61lqqsln264rlq4tt8dqm0